Metadate Er

Narcolepsy, Attention Deficit Hyperactivity Disorder

Treatment

20 Active Studies for Metadate Er

What is Metadate Er

Methylphenidate

The Generic name of this drug

Treatment Summary

Methylphenidate is a medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy. It is sold under the brand names Ritalin, Concerta, or Biphentin. Methylphenidate works by increasing the levels of dopamine and norepinephrine in the brain, which helps to improve focus, reduce impulsivity and hyperactivity, and increase cognitive function. Long-term studies have shown that methylphenidate is a safe and effective treatment for ADHD. It comes in both immediate-release and long-acting forms so that it can be taken once-daily for up

Methylphenidate Hydrochloride

is the brand name

image of different drug pills on a surface

Metadate Er Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Methylphenidate Hydrochloride

Methylphenidate

1955

490

Effectiveness

How Metadate Er Affects Patients

Methylphenidate is a combination of two forms of the same drug, one of which is more active than the other. It works by attaching to protein sites in certain parts of the brain, especially in an area that plays a role in Attention Deficit Hyperactivity Disorder (ADHD). In animal studies, methylphenidate was shown to increase movement and cause certain behaviors.

How Metadate Er works in the body

Methylphenidate helps to treat Attention Deficit Hyperactivity Disorder (ADHD) by increasing the presence of norepinephrine and dopamine in the brain. This helps to improve focus and attention, while also reducing impulsivity and movement. Research has shown that methylphenidate works by activating alpha-1 adrenergic receptor activity and overcoming any abnormalities in the dopamine transporter gene, D4 receptor gene, and D2 receptor gene.

When to interrupt dosage

The recommended measure of Metadate Er is contingent upon the given situation. The quantity of dosage is subject to the technique of delivery outlined in the table beneath.

Condition

Dosage

Administration

Attention Deficit Hyperactivity Disorder

20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Capsule, Capsule - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, chewable, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Suspension, extended release - Oral, Suspension, extended release, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral

Narcolepsy

20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Capsule, Capsule - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, chewable, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Suspension, extended release - Oral, Suspension, extended release, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral

Warnings

Metadate Er has fourteen contraindications and should not be taken concurrently with the ailments outlined in the table below.

Metadate Er Contraindications

Condition

Risk Level

Notes

advanced arteriosclerosis

Do Not Combine

Gilles de la Tourette syndrome

Do Not Combine

Thyrotoxicosis

Do Not Combine

Pulse Frequency

Do Not Combine

Open-angle glaucoma

Do Not Combine

Hypertensive disease

Do Not Combine

Pulse Frequency

Do Not Combine

Tension-Type Headache

Do Not Combine

Generalized Anxiety Disorder

Do Not Combine

symptomatic cardiovascular disease

Do Not Combine

Tourette Syndrome

Do Not Combine

Pheochromocytoma

Do Not Combine

Tics

Do Not Combine

Agitation

Do Not Combine

There are 20 known major drug interactions with Metadate Er.

Common Metadate Er Drug Interactions

Drug Name

Risk Level

Description

Desflurane

Major

Methylphenidate may increase the hypertensive activities of Desflurane.

Diethyl ether

Major

Methylphenidate may increase the hypertensive activities of Diethyl ether.

Enflurane

Major

Methylphenidate may increase the hypertensive activities of Enflurane.

Halothane

Major

Methylphenidate may increase the hypertensive activities of Halothane.

Isoflurane

Major

Methylphenidate may increase the hypertensive activities of Isoflurane.

Metadate Er Toxicity & Overdose Risk

Overdosing on methadone may lead to vomiting, restlessness, shaking, reflex over-sensitivity, muscle twitching, seizures that can lead to unconsciousness, euphoria, confusion, hallucinations, delirium, sweating, flushing, a headache, high fever, rapid heart rate, irregular heartbeats, high blood pressure, enlarged pupils, and dry mouth. The lowest toxic dose in mice has been found to be 190mg/kg when taken orally.

image of a doctor in a lab doing drug, clinical research

Metadate Er Novel Uses: Which Conditions Have a Clinical Trial Featuring Metadate Er?

84 active clinical trials are presently underway to assess the utility of Metadate ER in the management of Attention Deficit Hyperactivity Disorder.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

61 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Metadate Er Reviews: What are patients saying about Metadate Er?

5

Patient Review

1/2/2012

Metadate Er for Attention Deficit Disorder with Hyperactivity

I took this treatment for approximately one year. I found that it caused mood disturbances, depression, loss of appetite, headaches and stomach aches. Additionally, when I increased the dose I experienced agiation. Overall, I did not find it to be very helpful for ADHD symptoms.

4.7

Patient Review

11/12/2009

Metadate Er for Attention Deficit Disorder with Hyperactivity

I was prescribed this for possible adult ADD and it made my mood swings much worse. I would definitely not recommend it to others who are struggling with a similar issue.

4

Patient Review

1/28/2017

Metadate Er for Attention Deficit Disorder with Hyperactivity

This medication has been a lifesaver for my 16-year-old daughter. She used to have severe outbursts of anger, but since we switched her to metadate, they have decreased significantly. We recently increased her dose to 70 mg of extended release each morning, but it seems like the rages are starting to come back; so now we're also trying guanfacine in the afternoon.

3

Patient Review

5/7/2008

Metadate Er for Attention Deficit Disorder with Hyperactivity

2.7

Patient Review

9/2/2008

Metadate Er for Attention Deficit Disorder with Hyperactivity

I was prescribed this medicine recently, and it seems to be helping me.

2

Patient Review

2/6/2011

Metadate Er for Attention Deficit Disorder with Hyperactivity

I've been using this medication for a while now and it definitely helps me stay focused. If I don't take it, I can tell the difference in my concentration level.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about metadate er

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Metadate CD and Metadate ER?

"The once-a-day Metadate CD capsule has biphasic release, with a quick release of methylphenidate at first, followed by a continuous-release phase. Metadate ER, a tablet taken two to three times per day, can be adjusted so that midday doses are no longer necessary."

Answered by AI

Is methylphenidate ER the same as Adderall?

"Both Adderall and Ritalin are central nervous system stimulants used to treat attention deficit hyperactivity disorder, though Ritalin is milder in effect."

Answered by AI

What is Metadate ER used for?

"Medate ER is a drug used to manage the symptoms of Attention Deficit Hyperactivity Disorder and Narcolepsy. It can be used by itself of with other drugs, and is classified as a stimulant and ADHD agent."

Answered by AI

Is metadate the same as Ritalin?

"The active ingredient in Metadate CD is also found in medications like Ritalin and Daytrana, which may improve focus, and decrease impulsivity and hyperactive behavior in some patients with the condition."

Answered by AI

Clinical Trials for Metadate Er

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Metadate Er clinical trials?

We made a collection of clinical trials featuring Metadate Er, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Waitlist Available
Online Trial

The University of Texas at Austin

Have you considered Metadate Er clinical trials?

We made a collection of clinical trials featuring Metadate Er, we think they might fit your search criteria.
Go to Trials
Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA

The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.

Phase 4
Waitlist Available

Louisiana State University (+1 Sites)

Joshua M Langberg, PhD

Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Duke University

John Mitchell, PhD

Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Phase 1 & 2
Waitlist Available

Kennedy Krieger Institute

Alison E Pritchard, PhD

Image of Montana State University in Bozeman, United States.

Speech-Gesture Combinations for Autism

Any Age
All Sexes
Bozeman, MT

This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \[cry\], can promote successful understanding of words like "cry". The overarching goal is to help families effectively utilize gestures to support communication with their children.

Recruiting
Has No Placebo

Montana State University

Have you considered Metadate Er clinical trials?

We made a collection of clinical trials featuring Metadate Er, we think they might fit your search criteria.
Go to Trials